Drugs Containing Excipient (Inactive Ingredient) COCHINEAL

« Back to Dashboard

Branded drugs containing COCHINEAL excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	NEORAL	cyclosporine	0078-0246	COCHINEAL
ITERUM THERAPEUTICS US LIMITED	ORLYNVAH	sulopenem etzadroxil and probenecid	81153-100	COCHINEAL	2034-10-25

Generic drugs containing COCHINEAL excipient

Company	Ingredient	NDC	Excipient
Novartis Pharmaceuticals Corporation	cyclosporine	0078-0246	COCHINEAL
Walgreens	loratadine	0363-0754	COCHINEAL
TARGET CORPORATION	loratadine	11673-997	COCHINEAL
Ohm Laboratories Inc	loratadine	51660-754	COCHINEAL

Cochineal Pharmaceutical Excipient Market: Dynamics, Regulation, Patent Risk, and Financial Trajectory

Last updated: September 24, 2026

Cochineal is a natural red coloring agent used in pharmaceutical tablets, capsules, oral liquids, and nutraceutical products. Its commercial forms are cochineal extract and carmine, also called carminic acid aluminum lake. The market is established but niche. Demand is supported by clean-label formulation, natural-color substitution, and broad regulatory acceptance. Growth is constrained by insect-origin labeling, allergen concerns, batch variability, agricultural supply, religious and vegan restrictions, and competition from synthetic and non-insect natural colors.

Cochineal is not a conventional active pharmaceutical ingredient and is not generally protected by a drug-style composition-of-matter patent. Its commercial position depends more on regulatory status, supply qualification, color performance, traceability, and customer approvals than on exclusivity rights.

What is cochineal used for in pharmaceutical formulations?

Cochineal is used primarily as a color additive rather than as a functional therapeutic excipient.

Pharmaceutical dosage forms

Dosage form	Typical role of cochineal	Commercial relevance
Immediate-release tablets	Surface coating or tablet coloration	Established use
Hard gelatin capsules	Shell coloration	Important where a natural red color is required
Softgels	Shell coloration	Possible, subject to formulation compatibility
Oral liquids	Color adjustment and product identification	Limited by pH and stability requirements
Chewable tablets	Color and consumer appeal	Relevant in pediatric and consumer-health products
Topical products	Cosmetic coloration	Secondary use
Nutraceuticals	Capsule, gummy, and tablet color	Often larger opportunity than prescription pharmaceuticals

Cochineal extract contains carminic acid, the principal color-bearing compound. Carmine is a more processed aluminum-based lake pigment. The two materials are related but are not interchangeable for every regulatory filing or formulation specification.

Color performance depends on pH, light exposure, heat, metal ions, oxidation, and the composition of the dosage form. Carmine generally provides stronger and more stable red coloration than less processed cochineal extract, but both require formulation-specific testing.

How large is the cochineal pharmaceutical excipient market?

No authoritative public dataset separately reports global pharmaceutical revenue for cochineal. Industry sales are usually combined with food, beverage, cosmetics, nutraceutical, and industrial colorants. The pharmaceutical segment is therefore best assessed as a specialty submarket rather than as a standalone public financial category.

The financial structure is characterized by:

• low pharmaceutical volume relative to food applications;
• higher qualification value per customer;
• repeat demand after regulatory and formulation approval;
• long supplier-approval cycles;
• limited supplier switching once a product is commercialized;
• price sensitivity in high-volume generic products;
• stronger pricing power in specialty, pediatric, premium, and clean-label products.

A practical market model is:

Market driver	Effect on cochineal demand
Natural-color substitution	Positive
Clean-label positioning	Positive
Pharmaceutical capsule and coating demand	Positive
Vegan and vegetarian requirements	Negative
Insect-derived ingredient restrictions	Negative
Allergen disclosures	Negative
Batch-to-batch color variation	Negative
Supply from Peru, Mexico, and other producing regions	Positive but volatile
Synthetic red dye price advantage	Negative
Regulatory acceptance in major markets	Positive

The pharmaceutical portion is likely to remain a high-value, low-volume business. Revenue growth is more likely to come from pricing, product qualification, and geographic expansion than from major volume expansion.

What is the financial trajectory for cochineal suppliers?

The medium-term financial trajectory is positive but uneven. Revenue should benefit from natural-color demand, but margin performance will depend on raw-material costs, inventory management, and the ability to sell standardized, documented grades.

Revenue outlook

Period	Expected commercial pattern
Near term	Stable demand with selective growth in natural pharmaceutical and nutraceutical formulations
Medium term	Moderate growth from clean-label products and substitution away from petroleum-derived colors
Longer term	Continued specialty demand, offset by non-insect natural colors and labeling restrictions

Cochineal suppliers typically have greater exposure to food and beverage customers than to pharmaceutical customers. This creates operating leverage when large food customers increase orders, but it also makes supplier financial performance sensitive to consumer-product cycles.

The strongest commercial model is an integrated one that controls several stages:

1. insect cultivation or contracted agricultural supply;
2. extraction and pigment standardization;
3. pharmaceutical-grade manufacturing;
4. regulatory documentation;
5. formulation support;
6. global distribution.

Suppliers that only trade raw cochineal face weaker margins and greater price volatility. Suppliers that sell standardized carmine dispersions, coated-particle systems, or application-specific blends can capture higher margins.

Main cost drivers

The largest cost variables are insect biomass, labor, extraction yield, energy, purification, quality testing, regulatory compliance, and inventory. Agricultural disruptions can increase input costs quickly because the supply chain cannot be expanded immediately.

Pharmaceutical customers also require documentation that is more extensive than standard food specifications. Typical requirements include identity, assay, color strength, residual solvents, heavy metals, microbiological quality, pesticide residues, allergen controls, country of origin, and change-control procedures.

What regulatory status does cochineal have with the FDA?

The U.S. Food and Drug Administration permits cochineal extract and carmine as color additives under 21 C.F.R. § 73.100. The regulation covers specifications, permitted uses, and labeling requirements.

Carmine and cochineal extract must be declared by name on the label. Generic declarations such as "color added" are not sufficient for these ingredients because FDA requires consumers to be informed of their source and identity. FDA adopted this requirement after reports of serious allergic reactions associated with cochineal-derived colorants (U.S. Food and Drug Administration, 2009).

Cochineal is not an FDA-approved active drug ingredient. Its use in a pharmaceutical product is evaluated as part of the product’s overall formulation and manufacturing controls. The drug sponsor must establish that the color additive is appropriate for the intended dosage form and route of administration.

FDA regulatory implications

Issue	U.S. position
Regulatory category	Color additive
Pharmaceutical use	Permitted when consistent with applicable color-additive requirements
Label declaration	Cochineal extract or carmine must be identified
Orange Book listing	None for the excipient itself
Active-drug approval	Not applicable
Allergen consideration	Required in labeling and safety assessment
Pharmaceutical sponsor responsibility	Supplier qualification and formulation control

What is the European regulatory status of E120?

In the European Union, cochineal, carminic acid, and carmines are generally identified as E120. Their use is governed by the EU food-additive framework, including Regulation (EC) No. 1333/2008 and the purity specifications in Regulation (EU) No. 231/2012.

For medicines, pharmaceutical colorants must also comply with applicable European Pharmacopoeia and medicinal-product requirements. The presence of E120 in an approved product is determined by the product dossier, the applicable national or European authorization, and the finished-product labeling rules.

The EU framework is commercially important because it recognizes the ingredient but preserves source-transparency requirements. Pharmaceutical companies must account for local expectations concerning animal-derived materials, vegetarian status, and patient acceptability.

What patents protect cochineal and carmine?

No fundamental composition-of-matter patent is expected to protect naturally occurring cochineal, carminic acid, or conventional carmine. The underlying material is a naturally sourced pigment with a long history of use.

Potentially protectable subject matter includes:

• improved extraction methods;
• purification and decolorization processes;
• standardized pigment compositions;
• pH-stabilized formulations;
• encapsulated or coated color particles;
• controlled-release color systems;
• tablet-coating compositions;
• methods for improving light or heat stability;
• low-allergen or low-protein preparations;
• manufacturing processes that improve yield;
• combinations with other natural colorants.

The effective patent strength of this estate is therefore fragmented.

IP category	Expected protection	Commercial strength
Natural cochineal source material	Generally weak or unavailable	Low
Basic carminic acid extraction	Often vulnerable to prior art	Low to moderate
Purified pharmaceutical-grade composition	Possible	Moderate
Stabilized formulation	Possible	Moderate to strong
Application-specific coating system	Possible	Moderate
Manufacturing yield or purification process	Possible	Moderate
Supplier know-how and specifications	Non-patent protection	Often strong in practice

Trade secrets may be more important than patents. Extraction parameters, feedstock preparation, purification conditions, particle-size control, and color-standardization methods can be difficult for competitors to reproduce even when patent protection is limited.

What is the Orange Book status of cochineal?

Cochineal has no standalone Orange Book listing. The Orange Book identifies approved drug products and certain patents and exclusivities associated with those products. It does not create an exclusivity right for a common excipient or color additive.

Cochineal therefore has:

• no independent Orange Book patent listing;
• no standalone New Chemical Entity exclusivity;
• no excipient-based Paragraph IV pathway;
• no drug-product patent term tied to the pigment itself.

A generic applicant may use cochineal in a product if the formulation and regulatory requirements are satisfied. Patent risk would arise from the finished drug product, coating system, manufacturing process, or method of treatment, not from ordinary use of cochineal as a colorant.

When does cochineal lose exclusivity?

Cochineal has no single global exclusivity-loss date. Its basic use is not controlled by a central patent term. Competitive access is governed by regulatory approvals, supplier qualification, proprietary processes, and customer contracts.

A supplier may still obtain temporary commercial protection through:

• customer-specific specifications;
• confidential manufacturing know-how;
• exclusive distribution agreements;
• regional supply arrangements;
• proprietary stabilized dispersions;
• regulatory dossiers and change-control barriers.

These protections are commercial rather than equivalent to pharmaceutical exclusivity.

Are there Paragraph IV challenges or biosimilar risks for cochineal?

There are no meaningful Paragraph IV challenges directed at cochineal as an excipient. Paragraph IV litigation concerns patents listed for approved drug products in the FDA Orange Book. A color additive does not create a standalone Paragraph IV target.

Biosimilar risk is also not directly applicable. Biosimilar products may use cochineal or an alternative colorant, but the relevant competition concerns the biologic product, formulation, manufacturing process, and regulatory comparability. Cochineal itself does not create biosimilar exclusivity.

The greater substitution risk comes from alternative color systems:

• beetroot betalains;
• anthocyanins;
• paprika oleoresin;
• beta-carotene;
• turmeric-derived curcumin;
• spirulina-derived phycocyanin;
• synthetic FD&C colors;
• iron oxides and other inorganic pigments.

Which companies compete in the cochineal and natural-color market?

Competition is distributed across global color manufacturers, natural-ingredient suppliers, specialty pigment producers, and regional processors. Public disclosures often report natural colors as part of a broader portfolio rather than identifying cochineal revenue separately.

Relevant competitive groups include:

Competitor type	Strategic advantage
Global color manufacturers	Regulatory reach, technical service, multinational supply
Natural-color specialists	Formulation expertise and clean-label positioning
Agricultural processors	Access to raw cochineal and cost control
Pharmaceutical excipient distributors	Qualified supply and regional regulatory support
Synthetic-color suppliers	Lower cost and consistent performance
Integrated formulation suppliers	Application-specific blends and coating systems

The competitive advantage of a cochineal supplier depends on more than pigment availability. Customers value continuity of supply, pharmacopeial documentation, audit readiness, stability data, and a controlled change-notification process.

What manufacturing and IP barriers affect cochineal supply?

Cochineal production is tied to agricultural and biological inputs. The insects are cultivated on cactus hosts, harvested, dried, and processed. This creates several barriers:

Agricultural supply

Production is geographically concentrated and affected by weather, disease, water availability, labor, and changes in agricultural economics. Supply shocks can increase prices and extend lead times.

Standardization

Color strength varies with insect maturity, feedstock, drying conditions, extraction method, and storage. Pharmaceutical customers require tighter specifications than many food customers.

Contamination control

Manufacturers must control pesticides, microbial contamination, heavy metals, foreign matter, residual processing agents, and undeclared animal-derived materials.

Change control

A change in cultivation region, extraction solvent, processing site, or purification method can require customer notification and, in some cases, regulatory assessment. This makes supplier changes costly for drug manufacturers.

Process know-how

The strongest defensible advantage may reside in extraction yield, pigment recovery, impurity removal, and stable formulation performance. These capabilities are difficult to transfer rapidly between suppliers.

How does cochineal compare with synthetic red dyes?

Attribute	Cochineal/carmine	Synthetic red color
Source	Insect-derived	Manufactured chemical
Clean-label appeal	Strong	Weak to moderate
Vegan suitability	No	Usually yes
Batch consistency	Requires tight control	Generally high
Cost	Usually higher	Usually lower
Allergen concern	Documented concern	Depends on specific dye
Consumer acceptance	Strong in natural products, weak in insect-sensitive segments	Variable
Supply chain	Agricultural	Industrial
Pharmaceutical switching cost	Moderate to high after qualification	Moderate
Patent dependence	Low for basic material	Varies by formulation and process

Cochineal is most competitive where a red natural color is commercially important and the customer accepts insect origin. It is less competitive in vegan products, pediatric products requiring broad consumer acceptability, and low-cost generic products.

What generic launch risks exist for cochineal-containing medicines?

Generic launch risk is generally low from the excipient itself. A generic applicant can usually select a different colorant if the alternative meets formulation, labeling, stability, and regulatory requirements.

Risk increases when:

• the approved product’s appearance is part of product identification;
• the capsule shell has a proprietary color system;
• color affects dissolution or coating performance;
• the product has narrow stability margins;
• the reference product uses a difficult-to-reproduce shade;
• the sponsor has protected a proprietary coating formulation;
• the product is marketed with a natural-color claim.

Color changes can create regulatory, manufacturing, and commercial complications even when they do not create patent infringement. A generic company may therefore retain cochineal to match the reference product, but that decision reflects product-development economics rather than exclusivity.

What licensing deals and settlement agreements affect cochineal?

Publicly disclosed licensing and patent-settlement agreements focused specifically on cochineal are limited. The material is a commodity-like excipient and colorant rather than a patented drug platform.

Commercial agreements are more likely to involve:

• exclusive regional distribution;
• supply commitments;
• private-label manufacturing;
• formulation support;
• customer-specific specifications;
• technical-service arrangements;
• dual-sourcing and contingency inventory.

These agreements may restrict practical access to a grade without creating a legally enforceable monopoly over cochineal itself. No broad cochineal-related patent settlement framework comparable to branded-drug Paragraph IV settlements is apparent.

What is the commercial outlook for pharmaceutical cochineal?

The outlook is stable to moderately positive. Natural-color demand supports growth, while substitution and labeling concerns limit penetration.

The strongest growth opportunities are likely to occur in:

• premium oral medicines;
• pediatric and chewable formulations where red coloration supports product differentiation;
• nutraceuticals and supplements;
• capsule shells;
• clean-label over-the-counter products;
• markets with favorable acceptance of natural animal-derived ingredients.

The main downside risks are:

• vegan and vegetarian product policies;
• halal or kosher restrictions depending on certification and processing;
• consumer objections to insect-derived ingredients;
• allergic reactions and labeling scrutiny;
• improved performance of non-insect natural red colors;
• synthetic-color price advantages;
• climate and agricultural supply disruptions.

Key Takeaways

• Cochineal is a natural red colorant used mainly in tablets, capsules, oral liquids, and nutraceutical products.
• Its pharmaceutical market is niche and is not separately reported in most public financial datasets.
• Revenue growth should be moderate, supported by natural-color demand and constrained by insect-origin restrictions and alternative colorants.
• FDA permits cochineal extract and carmine under 21 C.F.R. § 73.100, subject to identity and labeling requirements.
• In the EU, cochineal and carmine are generally regulated as E120 under the food-additive framework, with medicinal-product requirements applying to pharmaceutical use.
• The basic pigment has little or no meaningful composition-of-matter exclusivity.
• Process patents, stabilized formulations, supplier know-how, and customer qualification create the main commercial barriers.
• Cochineal has no standalone Orange Book listing, Paragraph IV exposure, or biosimilar exclusivity.
• Generic-entry risk from the excipient is low, although switching colorants can create formulation and regulatory costs.
• Supplier strength depends on raw-material control, standardization, documentation, technical service, and supply continuity.

FAQs

Is cochineal considered a pharmaceutical excipient?

Cochineal is used as a pharmaceutical color additive and excipient, but it is not a therapeutic active ingredient. Its principal function is to color dosage forms.

Is carmine the same as cochineal extract?

No. Both are derived from cochineal insects and contain carminic-acid-based color, but carmine is a more processed aluminum lake pigment. Their specifications and regulatory treatment may differ.

Can vegan medicines use cochineal?

No. Cochineal and carmine are insect-derived and are generally unsuitable for vegan products. Manufacturers may use beetroot, anthocyanins, paprika, beta-carotene, or synthetic colors instead.

Does cochineal create an FDA drug-patent barrier?

No. Cochineal does not create a standalone FDA drug-patent barrier. Any patent issue would relate to a finished drug formulation, coating system, manufacturing method, or other product-specific technology.

Why do pharmaceutical companies continue using cochineal despite alternative colors?

Cochineal provides a strong natural red color and can match established product appearance. Once a formulation is approved and commercialized, retaining the qualified colorant may cost less than reformulating, conducting stability work, and managing a new regulatory submission.

References

1. European Commission. (2008). Regulation (EC) No. 1333/2008 on food additives. EUR-Lex. https://eur-lex.europa.eu/eli/reg/2008/1333/oj

2. European Commission. (2012). Commission Regulation (EU) No. 231/2012 laying down specifications for food additives listed in Annexes II and III to Regulation (EC) No. 1333/2008. EUR-Lex. https://eur-lex.europa.eu/eli/reg/2012/231/oj

3. U.S. Food and Drug Administration. (2009). Food labeling: Declaration of certifiable color additives. Federal Register, 74 Fed. Reg. 207. https://www.federalregister.gov

4. U.S. Food and Drug Administration. (n.d.). 21 C.F.R. § 73.100: Cochineal extract; carmine. Electronic Code of Federal Regulations. https://www.ecfr.gov/current/title-21/part-73/section-73.100

5. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/sda/sdNavigable.cfm?sd=inactiveingredientdatabase

6. World Health Organization. (n.d.). Combined compendium of food additive specifications. Joint FAO/WHO Expert Committee on Food Additives. https://www.fao.org/food/food-safety-quality/scientific-advice/jecfa/jecfa-additives/en/